Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s Alan Maine moves to Edelman

He joins the communications firm as its senior director

Alan MaineGlobal communications and marketing firm Edelman has strengthened its health public affairs capabilities with the addition of Alan Maine, who joins as its senior director.

Maine, who previously served as head of policy and public affairs at Pfizer UK, was responsible for government affairs and market access policy development activity, covering both corporate and therapy area public affairs.

During his time at Pfizer, Maine also worked with industry associations on campaigns, policies and initiatives relating to access to medicines.

He said: “I am delighted to be working with such a forward-looking company as Edelman and I am thrilled to work with the team to deliver innovative and strategic campaigns.”

Prior to his time with Pfizer, Maine was head of government affairs at Wyeth Pharmaceuticals - later acquired by Pfizer - and has held other roles with Merck Sharpe & Dohme.

Kate Hawker, managing director for Edelman UK, said: “We are very excited about Alan joining Edelman as he brings with him such great knowledge and insight of the complex challenges in the UK.”

5th February 2018

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....